Arcellx Inc (ACLX)

Feb 20, 2025

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - MSN

Feb 20, 2025

Feb 19, 2025

Arcellx (ACLX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Feb 19, 2025

Feb 19, 2025

Is Arcellx (ACLX) Poised to Capture Significant Market Share? - Yahoo Finance UK

Feb 19, 2025

Feb 18, 2025

Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update - MarketBeat

Feb 18, 2025

Feb 17, 2025

Arcellx, Inc. (NASDAQ:ACLX) Sees Large Increase in Short Interest - Defense World

Feb 17, 2025

Feb 15, 2025

(ACLX) Trading Advice - Stock Traders Daily

Feb 15, 2025

Feb 12, 2025

Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention - Benzinga

Feb 12, 2025

Feb 11, 2025

Arcellx Insiders Sold US$3.2m Of Shares Suggesting Hesitancy - Simply Wall St

Feb 11, 2025

Feb 10, 2025

Arcellx Inc’s Anito-cel: A Promising Investment with Innovative Therapeutics and Market Potential - TipRanks

Feb 10, 2025

Feb 08, 2025

Kavita Patel Sells 1,500 Shares of Arcellx, Inc. (NASDAQ:ACLX) Stock - MarketBeat

Feb 08, 2025

Feb 07, 2025

Financial Snapshot: Analyzing Arcellx Inc (ACLX)’s Key Ratio Metrics - The Dwinnex

Feb 07, 2025

Feb 07, 2025

Arcellx (NASDAQ:ACLX) Shares Down 5.4%What's Next? - MarketBeat

Feb 07, 2025

Feb 05, 2025

Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Increases By 6.6% - MarketBeat

Feb 05, 2025

Feb 05, 2025

Taking a Closer Look At Arcellx Inc (ACLX) Following Its Recent Trade - Knox Daily

Feb 05, 2025

Feb 05, 2025

arcellx director kavita patel sells $96,854 in stock - MSN

Feb 05, 2025

Feb 05, 2025

Financial Review: Arcellx (NASDAQ:ACLX) versus C4 Therapeutics (NASDAQ:CCCC) - Defense World

Feb 05, 2025

Feb 04, 2025

arcellx director kavita patel sells $96,854 in stock By Investing.com - Investing.com Australia

Feb 04, 2025

Feb 04, 2025

(ACLX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Feb 04, 2025

Feb 02, 2025

Brokerages Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - MarketBeat

Feb 02, 2025

Feb 02, 2025

Moody Aldrich Partners LLC Sells 16,122 Shares of Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat

Feb 02, 2025

Feb 02, 2025

Analysts Set Arcellx, Inc. (NASDAQ:ACLX) PT at $105.93 - Defense World

Feb 02, 2025

Jan 31, 2025

Vanguard Group Inc's Strategic Acquisition of Arcellx Inc Shares - GuruFocus.com

Jan 31, 2025

Jan 28, 2025

Stifel maintains Buy on Arcellx shares, target at $122 - MSN

Jan 28, 2025

Jan 28, 2025

Stifel maintains Buy on Arcellx shares, target at $122 By Investing.com - Investing.com Australia

Jan 28, 2025

Jan 23, 2025

(ACLX) On The My Stocks Page - Stock Traders Daily

Jan 23, 2025

Jan 23, 2025

Cantor Fitzgerald Estimates Arcellx FY2025 Earnings - Defense World

Jan 23, 2025

Jan 22, 2025

Brokers Issue Forecasts for Arcellx FY2025 Earnings - MarketBeat

Jan 22, 2025

Jan 20, 2025

Arcellx, Inc. (NASDAQ:ACLX) Sees Significant Growth in Short Interest - Defense World

Jan 20, 2025

Jan 19, 2025

Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Expands By 6.6% - MarketBeat

Jan 19, 2025

Jan 16, 2025

Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy - Seeking Alpha

Jan 16, 2025

Jan 15, 2025

Arcellx director Kavita Patel sells $98,801 in stock By Investing.com - Investing.com Australia

Jan 15, 2025

Jan 14, 2025

Arcellx, Inc. (NASDAQ:ACLX) Director Kavita Patel Sells 1,500 Shares - MarketBeat

Jan 14, 2025

Jan 14, 2025

Arcellx director Kavita Patel sells $98,801 in stock - Investing.com India

Jan 14, 2025

Jan 14, 2025

(ACLX)Analyzing Arcellx's Short Interest - Benzinga

Jan 14, 2025

Jan 13, 2025

Oversold Conditions For Arcellx (ACLX) - Nasdaq

Jan 13, 2025

Jan 10, 2025

Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 in Stock - MarketBeat

Jan 10, 2025

Jan 10, 2025

Arcellx's chief medical officer sells shares worth $581,315 By Investing.com - Investing.com Australia

Jan 10, 2025